THOMPSON JOHN CRAIG sold (to issuer) 79,873 shares of ESPR
THOMPSON JOHN CRAIG sold (to issuer) 79,873 shares of Esperion Therapeutics, Inc. (ESPR) on 2026-07-13.
How this was made
The 30-second read
Why it matters
The disclosure updates insider ownership records and may marginally influence sentiment, but it does not provide operational or financial guidance changes.
Market read
Traders may note the director’s completed position (0 shares after transaction), but the lack of price/value and the code D mechanics limit tradable signal strength.
What to watch
The filing states no 10b5-1 plan and does not disclose price or total value; also, code D (sale to issuer) can reflect buyback participation or other mechanical processes, reducing interpretability.
Background
This is an SEC Form 4 insider transaction for Esperion Therapeutics, reported by a director (John Craig Thompson) as a sale to the issuer (code D).
Ticker impact
Esperion Therapeutics disclosed a director sale to the issuer of 79,873 shares on 2026-07-13 via Form 4.
Low likelihood of a sustained price move; any reaction is likely muted and short-lived.
The filing is a primary-source Form 4, but the transaction details provide no price, value, or stated catalyst, and the director ends with 0 shares, which is not necessarily informative without context (e.g., planned liquidity or buyback mechanics).
Market effects
Minimal read-across to the biotech sector; this is an issuer-specific insider liquidity disclosure.
None.
None.
Counterpoint
Ending with 0 shares could be interpreted as a stronger negative signal if the sale was discretionary rather than part of a structured program.
Key entities
- issuerEsperion Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderTHOMPSON JOHN CRAIG
Director reporting a sale to the issuer of 79,873 shares on 2026-07-13.